161 related articles for article (PubMed ID: 33423421)
1. PD1 inhibitor induced inverse lichenoid eruption: a case series.
Sethi M; Garg V; Lee JB; Yang S
Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423421
[TBL] [Abstract][Full Text] [Related]
2. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
3. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
4. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
6. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
[TBL] [Abstract][Full Text] [Related]
7. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
[TBL] [Abstract][Full Text] [Related]
8. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
9. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases.
Chou S; Zhao C; Hwang SJE; Fernandez-Penas P
J Cutan Pathol; 2017 Oct; 44(10):851-856. PubMed ID: 28753231
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
[TBL] [Abstract][Full Text] [Related]
11. Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
Varma A; Friedlander P; De Moll EH; Desman G; Levitt J
Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621697
[TBL] [Abstract][Full Text] [Related]
12. Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis.
Ghiam N; Ojong O; Vasile G; Romanelli P; Kerdel F
Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423430
[TBL] [Abstract][Full Text] [Related]
13. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
14. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.
Wahiduzzaman M; Pubalan M
Dermatol Online J; 2008 Dec; 14(12):14. PubMed ID: 19265627
[TBL] [Abstract][Full Text] [Related]
15. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Fixsen E; Patel J; Selim MA; Kheterpal M
Oncologist; 2019 Mar; 24(3):e103-e105. PubMed ID: 30617087
[TBL] [Abstract][Full Text] [Related]
16. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
Freites-Martinez A; Kwong BY; Rieger KE; Coit DG; Colevas AD; Lacouture ME
JAMA Dermatol; 2017 Jul; 153(7):694-697. PubMed ID: 28467522
[TBL] [Abstract][Full Text] [Related]
17. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab.
McCormick BJ; Zieman D; West-Santos C; Phillips MB
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37339826
[TBL] [Abstract][Full Text] [Related]
19. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
20. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
